Rick Gon­za­lez lays out plan for in­ter­nal can­di­date to take over as Ab­b­Vie's CEO

Rick Gon­za­lez, Ab­b­Vie’s found­ing CEO, is work­ing on his ex­it af­ter more than a decade at the helm — and it’s go­ing to be an in­ter­nal can­di­date.

Gon­za­lez first an­nounced the hunt for his suc­ces­sor last year, which in­clud­ed his plans to stay un­til the com­pa­ny nav­i­gat­ed the loss of Hu­mi­ra ex­clu­siv­i­ty and “the rest of the busi­ness is per­form­ing at a high lev­el.”

Rev­enue from its im­munol­o­gy port­fo­lio came in about 10% low­er, at $26 bil­lion in 2023, due to biosim­i­lar com­pe­ti­tion for Hu­mi­ra, but it’s not all bad news. Ab­b­Vie raised its long-term out­look for Skyrizi and Rin­voq, say­ing it now ex­pects com­bined rev­enues of more than $27 bil­lion in 2027. That’s about $6 bil­lion high­er than pre­vi­ous guid­ance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER